Home › Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial...
 

Keywords :   


Daiichi Sankyo and ArQule Announce Top-Line Results of Phase 2 Trial...

2013-01-12 04:25:40| Biotech - Topix.net

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced the top-line results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer .

Tags: results trial phase announce

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Best No Bake Recipes Due by January 1
30.09The One-Room Schoolhouse
30.09Youth Tour: A Living Example of Cooperative Values
30.09Soaring Success
30.09Bunning enters supply agreement with Vermeer
30.09Santa Rosa County, Fla. Delays New Recycling Contract with WM
30.09Winters Bros. Scrap Plans for Waste Transfer Station in Yaphank, NY
30.09Aston Martin shares shaken after profit warning
More »